Type I interferon-mediated tumor immunity and its role in immunotherapy
R Yu, B Zhu, D Chen - Cellular and Molecular Life Sciences, 2022 - Springer
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …
in patients with many different types of cancer; however, most patients who receive ICB …
Antitumour actions of interferons: implications for cancer therapy
BS Parker, J Rautela, PJ Hertzog - Nature Reviews Cancer, 2016 - nature.com
The interferons (IFNs) are a family of cytokines that protect against disease by direct effects
on target cells and by activating immune responses. The production and actions of IFNs are …
on target cells and by activating immune responses. The production and actions of IFNs are …
Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
Intratumoral immunotherapy is an emerging modality for the treatment of solid tumors. Toll-
like receptor (TLR) agonists have shown promise for eliciting immune responses, but …
like receptor (TLR) agonists have shown promise for eliciting immune responses, but …
Type I interferons in anticancer immunity
Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this
Review, we discuss accumulating evidence indicating that type I IFNs produced by …
Review, we discuss accumulating evidence indicating that type I IFNs produced by …
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
Abstract Toll-like receptors (TLRs), which serve as a bridge between innate and adaptive
immunity, may be viable treatment targets. TLRs are the first line of defense against …
immunity, may be viable treatment targets. TLRs are the first line of defense against …
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli… - …, 2014 - Taylor & Francis
Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit
immune responses specific for dead cell-associated antigens. However, multiple stimuli can …
immune responses specific for dead cell-associated antigens. However, multiple stimuli can …
Combinatorial strategies for the induction of immunogenic cell death
L Bezu, LC Gomes-da-Silva, H Dewitte… - Frontiers in …, 2015 - frontiersin.org
The term “immunogenic cell death”(ICD) is commonly employed to indicate a peculiar
instance of regulated cell death (RCD) that engages the adaptive arm of the immune system …
instance of regulated cell death (RCD) that engages the adaptive arm of the immune system …
[HTML][HTML] Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade
in different types of metastatic cancers. Such data underscore that immunotherapy is one of …
in different types of metastatic cancers. Such data underscore that immunotherapy is one of …
Trial watch: IDO inhibitors in cancer therapy
E Vacchelli, F Aranda, A Eggermont… - …, 2014 - Taylor & Francis
Indoleamine 2, 3-dioxigenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-
limiting step of the so-called “kynurenine pathway”, ie, the metabolic cascade that converts …
limiting step of the so-called “kynurenine pathway”, ie, the metabolic cascade that converts …
Trial watch: TLR3 agonists in cancer therapy
ABSTRACT Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …